Drug pricing regulator National Pharmaceutical Pricing Authority (NPPA) has revised ceiling prices of 4 scheduled formulations of Scheduled-I under Drug (Price Control) Amendment Order, 2016 and retail price of one formulation under DPCO, 2013.The scheduled formulations are Clotrimazole cream 1%, Ceftriaxone Powder for Injection 1gm, Erythropoietin Injection 2000 IU/ml and Erythropoietin Injection 10000 IU/ml and Monocef-SB 125 mg Injection.
The concerned manufacturers of these formulations shall furnish quarterly return to the NPPA, in respect of production/import and sale of product in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Manufacturers in case intending to discontinue above said formulations, shall furnish information to the NPPA, in respect of discontinuation of the production and/or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
In case the retail price of any of the formulations is not complied with, as per instant price notification and notes specified, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
Every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
